Found 19 renal-electrolyte-and-hypertension trials
A listing of renal-electrolyte-and-hypertension medical research trials actively recruiting patient volunteers. Search for closest city to find more detailed information on a research study in your area.
A Randomized, Double-Blind, Placebo-Controlled, Phase 3 Study of the Safety and Efficacy of OMS721 in Patients with Immunoglobulin A (IgA) Nephropathy (ARTEMIS-IgAN)
Phase 3
This study will use a new investigational study drug called OMS721 in people with Immunoglobulin A (IgA) Nephropathy. This kidney disease produces abnormal amounts of a protein called IgA in the kidney that damage the filtering units or glomeruli. Glomeruli are tiny filtering units in the kidney that remove excess …
The Nephrotic Syndrome Study Network
The Nephrotic Syndrome Study Network (NEPTUNE) is a multi-disciplinary, multi-center longitudinal observational study. The main purpose of this study is to find markers for progression of Nephrotic Syndrome. We are particularly interested in the diseases called Focal and Segmental Glomerulosclerosis (FSGS), Minimal Change Disease (MCD), and Membranous Nephropathy (MN), which …
PGDD
PURPOSE Our aim is to create a comprehensive glomerular disease database at the Hospital of the University of Pennsylvania. The database will aid researchers in rapid selection of patients for recruitment to multi-center studies and trials and allow basic characterization of patients. The databank will have 2 parts A. an …
Study to Evaluate the Efficacy and Safety of Nefecon Treatment in Patients With IgA Nephropathy Who Have Completed Study Nef-301
This is a Phase 3b, multicenter, open-label extension (OLE) study to evaluate the efficacy and safety of Nefecon treatment in patients with IgAN who have completed the Phase 3 Study Nef 301 and continue to be treated with a stable dose of RAS inhibitor therapy (ACEIs and/or ARBs). Patients who …
CureGN-Diabetes: Ancillary Study to CureGN
There are several different types of glomerular diseases, such as minimal change disease (MCD), focal segmental glomerulosclerosis (FSGS), membranous nephropathy (MN), and immunoglobulin A nephropathy (IgAN). Over time, these diseases may cause kidney damage. Because these kidney diseases are rare, it is difficult for individual researchers to gather a large …
TRIDENT 2.0
Primary Objective --To evaluate the hypothesis that the SGLT2 inhibitor, dapagliflozin, alters kidney molecular pathways associated with progression of diabetic kidney disease Secondary Objectives --To evaluate relationships between changes in kidney molecular fingerprints and changes in kidney function --To identify factors associated with changes in kidney molecular fingerprints --To evaluate …
EnLight
This registry is an observational study designed to assess the utilization and effectiveness of LUPKYNIS in patients with lupus nephritis (LN) in the U.S. This registry is intended to benefit and support interests of patients, clinicians, regulatory bodies, payers, and industry by obtaining longitudinal data on LUPKYNIS.
CARSK
CARSK aims to test the hypothesis that after screening for wait list entry, no further screening for coronary artery disease (CAD) is non-inferior to the current standard care, which is screening all asymptomatic wait-listed patients for CAD at regular intervals, and to compare the benefits and costs of not screening …
Mineralys MLS-101-202
PURPOSE To assess the blood pressure (BP) lowering effect of lorundrostat taken once daily, compared with placebo, in subjects with uncontrolled hypertension Change in 24-hour mean ambulatory blood pressure monitoring (ABPM) SBP from Week 0 (randomization) to Week 12 Change in automated office blood pressure (AOBP) SBP from Week 0 …
IMAGINE (Interleukin 6 Blockade Modifying Antibody-Mediated Graft INjury and eGFR Decline)
Evaluate efficacy and safety of clazakizumab in preventing allograft loss in kidney transplant recipients. See section 3.1 of protocol. See section 3.2 of protocol.
1 - 10 of 19
- 1
- 2
